Literature DB >> 35349050

Cardio-Oncology Care Delivered in the Non-academic Environment.

Anita M Arnold1, Kerry Skurka2.   

Abstract

OPINION STATEMENT: It is a fact that the field of Cardio-Oncology is growing rapidly throughout the USA and abroad. Cancer and heart disease continue to be the leading causes of death in the USA, and oncologic therapies are evolving to the point that cancer survivors are increasing yearly, some living long enough to develop cardiovascular disease, and others living with sequelae from their cancer therapy. The financial burdens to the healthcare system continue to present barriers for the delivery of healthcare, especially for patients with heart disease and cancer as chronic diseases. Collaboration between cardiologists and oncologists is paramount to ensure timely cancer care while minimizing cardiotoxicity. The field of Cardio-Oncology is the perfect model for the current management of these patients, positioned to break down silos, avoid delays in cancer care, and treating potential short- and long-term sequela of cancer therapy in a cost-efficient manner. While cardio-oncology programs initially sprang from the academic and defined cancer centers, it is rapidly growing in the nonacademic settings. This paper explores reasons that occurred and explores some of the unique aspects to cancer care and cardio-oncology delivery in the nonacademic setting. The ultimate goal is to achieve the best cancer care with the least degree of disruption to therapy that also minimizes cardiotoxicity, lowering costs, and improving outcomes for patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardio-oncology program development; Care delivery; Community/non-academic cancer care

Mesh:

Year:  2022        PMID: 35349050     DOI: 10.1007/s11864-022-00978-w

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  12 in total

1.  The problem of fragmentation and the need for integrative solutions.

Authors:  Kurt C Stange
Journal:  Ann Fam Med       Date:  2009 Mar-Apr       Impact factor: 5.166

Review 2.  Cancer Survivorship.

Authors:  Charles L Shapiro
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

3.  Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma.

Authors:  Caitlin A Hester; Nishika Karbhari; Nicole E Rich; Mathew Augustine; John C Mansour; Patricio M Polanco; Matthew R Porembka; Sam C Wang; Herbert J Zeh; Amit G Singal; Adam C Yopp
Journal:  Cancer       Date:  2019-07-12       Impact factor: 6.860

Review 4.  Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.

Authors:  Farzad Masoudkabir; Nizal Sarrafzadegan; Carolyn Gotay; Andrew Ignaszewski; Andrew D Krahn; Margot K Davis; Christopher Franco; Arya Mani
Journal:  Atherosclerosis       Date:  2017-06-02       Impact factor: 5.162

Review 5.  Implementing a Cardio-oncology Center of Excellence: Nuts and Bolts, Including Coding and Billing.

Authors:  Anita M Arnold; Cathleen Biga
Journal:  Cardiol Clin       Date:  2019-11       Impact factor: 2.213

6.  Cost differential by site of service for cancer patients receiving chemotherapy.

Authors:  Jad Hayes; Russell J Hoverman; Matthew E Brow; Dana C Dilbeck; Diana K Verrilli; Jody Garey; Janet L Espirito; Jorge Cardona; Roy Beveridge
Journal:  Am J Manag Care       Date:  2015-03-01       Impact factor: 2.229

Review 7.  Developing a Comprehensive Cardio-Oncology Program at a Cancer Institute: The Moffitt Cancer Center Experience.

Authors:  Michael G Fradley; Allen C Brown; Bernadette Shields; Federico Viganego; Rongras Damrongwatanasuk; Aarti A Patel; Gregory Hartlage; Natalee Roper; Julie Jaunese; Larry Roy; Roohi Ismail-Khan
Journal:  Oncol Rev       Date:  2017-07-18

8.  Preventive Cardio-Oncology: The Time Has Come.

Authors:  Sherry-Ann Brown
Journal:  Front Cardiovasc Med       Date:  2020-01-10

9.  Cancer and heart disease: associations and relations.

Authors:  Rudolf A de Boer; Wouter C Meijers; Peter van der Meer; Dirk J van Veldhuisen
Journal:  Eur J Heart Fail       Date:  2019-07-18       Impact factor: 15.534

Review 10.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Authors:  Luca Falzone; Salvatore Salomone; Massimo Libra
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.